Mariner
ELDN icon

Mariner’s Eledon Pharmaceuticals ELDN Stock Holding History

Mariner’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Buy
+50,041
New +$182K ﹤0.01% 3159
2026
Q1 		– Sell
-12,414
Closed -$18.7K – 3640
2025
Q4 		$18.7K Buy
+12,414
New +$29.5K ﹤0.01% 3487

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Mariner's ELDN Position: Q2 2026 in Review

Mariner opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 50,041 shares worth $197K. The stake represents ﹤0.01% of the portfolio and ranks #3159 among its holdings. This is a return to the name: Mariner previously reported a position in ELDN as recently as Q4 2025.

Mariner first reported a position in ELDN in Q4 2025 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Mariner held 50,041 shares of Eledon Pharmaceuticals worth $197K as of Q2 2026.
  • Eledon Pharmaceuticals was a new Mariner position in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3159 holding.
  • Mariner first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.